Ozturk, Teoman
Mignot, Julien
Gattazzo, Francesca
Gervais, Marianne
Relaix, Frédéric
Rouard, Hélène
Didier, Nathalie http://orcid.org/0000-0003-4144-7581
Funding for this research was provided by:
AFM-Téléthon (Translamuscle PROJECT 19507)
Agence Nationale de la Recherche (ANR-22-ASTR-0034 HydrACell)
Fondation des Gueules Cassées (Dossier n°59)
Article History
Received: 3 April 2024
Accepted: 8 June 2024
First Online: 21 June 2024
Declarations
:
: Mice. C57BL/6NRj mice were purchased from Janvier Labs. Genetically modified mouse lines used in this study have been described and kindly provided by the corresponding laboratories: <i>Tg:Pax7nGFP</i> [], <i>Pax7</i><sup><i>CreERT2</i></sup> [], <i>Rosa26iDTR-loxP</i> [] and <i>Rag2</i><sup><i>−/−</i></sup><i>γC</i><sup><i>−/−</i></sup> []. <i>Rosa</i><sup><i>nT−nG</i></sup> mice [] were provided by P. Maire laboratory (Cochin Institute, Paris). Animals were handled according to French and European Community guidelines (title of the approved project: Cell therapy strategies for skeletal muscle repair, approval number: APAFIS#11249-2017091311274483, Animal experimentation ethic comitee: n°16, date of approval: 14 December 2018). Human muscle biopsies. Human biopsies were obtained under the approval of the French Biomedicine Agency (title of the approved Project: ENDO-COV 19, Approval no.: PFS21-008, handled by the Bioethic Cell of the General Direction of Research and Innovation, date of approval: 4 May 2021). Biopsies were obtained from brain-dead organ donors individuals, with the informed consent of the relatives.
: Not applicable.
: The authors declare no competing interests.